Trial Profile
A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects With FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Quizartinib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Ambit Biosciences Corporation; Astellas Pharma; Daiichi Sankyo Inc
- 29 Jun 2020 Results evaluating the population pharmacokinetics (PK) of quizartinib and its active metabolite published in the Journal of Clinical Pharmacology
- 06 Nov 2019 Results of analysis of two clinical studies: a phase 3 QuANTUM-R trial and a phase 2 study APS2689-CL-2004, evaluating exposure response relationships across various efficacy endpoints of quizartinib, release in 61st Annual Meeting and Exposition of the American Society of Hematology
- 06 Nov 2019 Results of pooled data from four studies: one phase 3 (QuANTUM-R), two phase 2, (ACC220-002 and 2689-CL-2004), and one phase 1 (CP0001), released at the 61st Annual Meeting and Exposition of the American Society of Hematology.